SAFINAMIDE MESYLATE
Post-LOEANDAORALTABLET
Approved
Jun 2023
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SAFINAMIDE MESYLATE by Aurobindo Pharma is unknown. First approved in 2023.
Drug data last refreshed 19h ago
Mechanism of Action
unknown. XADAGO is an inhibitor of monoamine oxidase B (MAO-B). Inhibition of MAO-B activity, by blocking the catabolism of dopamine, is thought to result in an increase in dopamine levels and a subsequent increase in dopaminergic activity in the brain.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on SAFINAMIDE MESYLATE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.